Trade Mustang Bio, Inc. - MBIO CFD

Add to favourite

1.34

2.19%

View detailed chart

To be able to trade stocks like this, create an account and apply for a stock listing.

Create Account

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow
Ownership

Trading Conditions

Spread

0.09

Long position overnight fee

-0.026235%

Short position overnight fee

0.004012%

Overnight fee time

22:00 (UTC)

Min traded quantity

Currency

USD

Margin

Stock exchange

United States of America

Commission on trade

*Information provided by Capital.com

Key Stats

Prev. Close*	1.37
Open*	1.43
1-Year Change*	197.92%
Day's Range*	1.34 - 1.44
52 wk Range	0.32-1.16
Average Volume (10 days)	276.10K
Average Volume (3 months)	8.77M
Market Cap	40.10M
P/E Ratio	-100.00K
Shares Outstanding	110.24M
Revenue	N/A
EPS	-0.75
Dividend (Yield %)	N/A
Beta	1.87
Next Earnings Date	May 10, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Dec 1, 2023	1.34	-0.09	-6.29%	1.43	1.44	1.34
Nov 30, 2023	1.37	-0.02	-1.44%	1.39	1.41	1.34
Nov 29, 2023	1.39	-0.02	-1.42%	1.41	1.44	1.38
Nov 28, 2023	1.41	-0.07	-4.73%	1.48	1.52	1.38
Nov 27, 2023	1.50	-0.14	-8.54%	1.64	1.64	1.49
Nov 24, 2023	1.57	0.03	1.95%	1.54	1.64	1.48
Nov 22, 2023	1.49	-0.02	-1.32%	1.51	1.54	1.42
Nov 21, 2023	1.48	-0.18	-10.84%	1.66	1.66	1.48
Nov 20, 2023	1.62	0.04	2.53%	1.58	1.73	1.58
Nov 17, 2023	1.58	0.10	6.76%	1.48	1.65	1.48
Nov 16, 2023	1.52	-0.01	-0.65%	1.53	1.55	1.48
Nov 15, 2023	1.48	-0.06	-3.90%	1.54	1.61	1.47
Nov 14, 2023	1.54	-0.05	-3.14%	1.59	1.59	1.42
Nov 13, 2023	1.49	-0.06	-3.87%	1.55	1.55	1.44
Nov 10, 2023	1.53	-0.11	-6.71%	1.64	1.64	1.46
Nov 9, 2023	1.62	0.01	0.62%	1.61	1.66	1.56
Nov 8, 2023	1.70	-0.16	-8.60%	1.86	1.86	1.68
Nov 7, 2023	1.81	0.02	1.12%	1.79	1.93	1.74
Nov 6, 2023	1.77	-0.01	-0.56%	1.78	1.83	1.73
Nov 3, 2023	1.71	0.18	11.76%	1.53	1.76	1.53

Mustang Bio, Inc. Events

Time (UTC)	Country	Event
No events scheduled

View all events

Annual
Quarterly

	2022	2021	2020	2019	2018
Total revenue	0	0	0	0	0
Total Operating Expense	76.159	66.723	56.806	45.885	31.223
Selling/General/Admin. Expenses, Total	12.21	11.017	9.505	9.57	6.759
Research & Development	61.249	53.506	45.601	36.315	24.464
Operating Income	-76.159	-66.723	-56.806	-45.885	-31.223
Interest Income (Expense), Net Non-Operating	-2.67	0.353	-3.209	-0.504	0.561
Net Income Before Taxes	-77.525	-66.37	-60.015	-46.389	-30.662
Net Income After Taxes	-77.525	-66.37	-60.015	-46.389	-30.662
Net Income Before Extra. Items	-77.525	-66.37	-60.015	-46.389	-30.662
Net Income	-77.525	-66.37	-60.015	-46.389	-30.662
Income Available to Common Excl. Extra. Items	-77.525	-66.37	-60.015	-46.389	-30.662
Income Available to Common Incl. Extra. Items	-77.525	-66.37	-60.015	-46.389	-30.662
Dilution Adjustment
Diluted Net Income	-77.525	-66.37	-60.015	-46.389	-30.662
Diluted Weighted Average Shares	103.433	87.8852	52.5888	36.0618	26.9494
Diluted EPS Excluding Extraordinary Items	-0.74952	-0.75519	-1.14121	-1.28637	-1.13776
Dividends per Share - Common Stock Primary Issue
Diluted Normalized EPS	-0.74952	-0.75519	-1.14121	-1.28637	-1.13776
Revenue				0	0
Total Extraordinary Items
Depreciation / Amortization	2.7	2.2	1.7
Other, Net	1.304

	Dec 2022	Sep 2022	Jun 2022	Mar 2022	Dec 2021
Total revenue	0	0	0	0	0
Total Operating Expense	19.432	18.848	18.241	19.638	20.119
Selling/General/Admin. Expenses, Total	2.395	3.389	3.077	3.349	2.646
Research & Development	16.337	14.759	14.464	15.689	16.773
Depreciation / Amortization	0.7	0.7	0.7	0.6	0.7
Operating Income	-19.432	-18.848	-18.241	-19.638	-20.119
Interest Income (Expense), Net Non-Operating	-0.837	-0.818	-0.858	-0.157	0.07
Net Income Before Taxes	-19.634	-18.997	-19.099	-19.795	-20.049
Net Income After Taxes	-19.634	-18.997	-19.099	-19.795	-20.049
Net Income Before Extra. Items	-19.634	-18.997	-19.099	-19.795	-20.049
Net Income	-19.634	-18.997	-19.099	-19.795	-20.049
Income Available to Common Excl. Extra. Items	-19.634	-18.997	-19.099	-19.795	-20.049
Income Available to Common Incl. Extra. Items	-19.634	-18.997	-19.099	-19.795	-20.049
Diluted Net Income	-19.634	-18.997	-19.099	-19.795	-20.049
Diluted Weighted Average Shares	106.863	105.918	102.947	97.9149	92.0797
Diluted EPS Excluding Extraordinary Items	-0.18373	-0.17936	-0.18552	-0.20217	-0.21774
Dividends per Share - Common Stock Primary Issue		0	0	0
Diluted Normalized EPS	-0.18373	-0.17936	-0.18552	-0.20217	-0.21774
Other, Net	0.635	0.669

Annual
Quarterly

	2022	2021	2020	2019	2018
Total Current Assets	78.852	111.706	99.534	63.063	35.125
Cash and Short Term Investments	75.656	109.618	97.804	61.413	34.073
Cash & Equivalents	75.656	109.618	97.804	61.413	16.469
Total Assets	92.422	125.17	109.9	73.445	42.754
Total Current Liabilities	15.109	10.815	9.515	7.771	5.617
Payable/Accrued					5.381
Accrued Expenses	7.628	6.749	5.639	4.109	0.236
Notes Payable/Short Term Debt	0	0	0	0	0
Other Current Liabilities, Total	0.648	0.554	0.358	0.535
Total Liabilities	46.149	12.77	11.465	21.793	6.358
Total Long Term Debt	27.436	0	0	12.179	0
Total Equity	46.273	112.4	98.435	51.652	36.396
Redeemable Preferred Stock				0	0
Common Stock	1.12	4.33808	7.94608	4.927	2.088
Additional Paid-In Capital	374.522	359.906	275.963	172.184	113.378
Retained Earnings (Accumulated Deficit)	-329.369	-251.844	-185.474	-125.459	-79.07
Total Liabilities & Shareholders’ Equity	92.422	125.17	109.9	73.445	42.754
Total Common Shares Outstanding	107.347	94.4284	71.7661	40.2489	27.6102
Short Term Investments				0	17.604
Total Receivables, Net	0.036	0.05	0.015	0.019	0.037
Prepaid Expenses	3.16	2.038	1.715	1.631	1.015
Property/Plant/Equipment, Total - Net	12.309	12.102	9.116	9.132	6.858
Other Long Term Assets, Total	1.261	1.362	1.25	1.25	0.771
Other Liabilities, Total	3.604	1.955	1.95	1.843	0.741
Property/Plant/Equipment, Total - Gross	20.71	17.836	12.683	11.022	7.49
Accumulated Depreciation, Total	-8.401	-5.734	-3.567	-1.89	-0.632
Accounts Payable	6.833	3.512	3.518	1.877
Current Port. of LT Debt/Capital Leases			0	1.25
Long Term Debt	27.436		0	12.179
Preferred Stock - Non Redeemable, Net	0	0	0
Other Equity, Total		-0.00008	-0.00008

	Dec 2022	Sep 2022	Jun 2022	Mar 2022	Dec 2021
Total Current Assets	78.852	94.447	109.376	124.153	111.706
Cash and Short Term Investments	75.656	91.364	107.369	122.216	109.618
Cash & Equivalents	75.656	91.364	107.369	122.216	109.618
Total Receivables, Net	0.036	0.033	0.033	0.032	0.05
Prepaid Expenses	3.16	3.05	1.974	1.905	2.038
Total Assets	92.422	108.836	121.905	136.961	125.17
Property/Plant/Equipment, Total - Net	12.309	13.069	11.17	11.522	12.102
Property/Plant/Equipment, Total - Gross	20.71	20.742	18.202	17.896	17.836
Accumulated Depreciation, Total	-8.401	-7.673	-7.032	-6.374	-5.734
Other Long Term Assets, Total	1.261	1.32	1.359	1.286	1.362
Total Current Liabilities	15.109	13.557	10.981	10.784	10.815
Accounts Payable	6.833	7.005	5.441	5.54	3.512
Payable/Accrued
Accrued Expenses	7.628	5.788	4.966	4.798	6.749
Notes Payable/Short Term Debt	0	0	0	0	0
Other Current Liabilities, Total	0.648	0.764	0.574	0.446	0.554
Total Liabilities	46.149	44.511	39.897	39.63	12.77
Total Long Term Debt	27.436	27.293	27.15	26.986	0
Other Liabilities, Total	3.604	3.661	1.766	1.86	1.955
Total Equity	46.273	64.325	82.008	97.331	112.4
Redeemable Preferred Stock
Common Stock	1.12	0.015	0.038	0.03708	4.33808
Additional Paid-In Capital	374.522	374.045	372.708	368.933	359.906
Retained Earnings (Accumulated Deficit)	-329.369	-309.735	-290.738	-271.639	-251.844
Other Equity, Total				-0.00008	-0.00008
Total Liabilities & Shareholders’ Equity	92.422	108.836	121.905	136.961	125.17
Total Common Shares Outstanding	107.347	107.273	105.357	101.133	94.4284
Preferred Stock - Non Redeemable, Net	0	0	0	0	0
Long Term Debt	27.436	27.293	27.15	26.986

Annual
Quarterly

	2022	2021	2020	2019	2018
Net income/Starting Line	-77.525	-66.37	-60.015	-46.389	-30.662
Cash From Operating Activities	-65.066	-53.667	-37.319	-33.581	-19.244
Non-Cash Items	5.706	11.173	17.926	11.418	8.32
Cash Interest Paid	2.71	0	1.593	1.057	0
Changes in Working Capital	4.03	-0.637	3.093	0.132	2.468
Cash From Investing Activities	-2.952	-5.366	-4.412	13.909	0.557
Other Investing Cash Flow Items, Total	-0.238	-1.38	-2.487	16.254	7.427
Cash From Financing Activities	34.056	70.847	78.122	65.116	0.181
Issuance (Retirement) of Stock, Net	6.829	72.228	97.384	54.14	0.181
Issuance (Retirement) of Debt, Net	30	0	-15.75	15	0
Net Change in Cash	-33.962	11.814	36.391	45.444	-18.506
Cash From Operating Activities	2.723	2.167	1.677	1.258	0.63
Capital Expenditures	-2.714	-3.986	-1.925	-2.345	-6.87
Financing Cash Flow Items	-2.773	-1.381	-3.512	-4.024

	Dec 2022	Sep 2022	Jun 2022	Mar 2022	Dec 2021
Net income/Starting Line	-77.525	-57.891	-38.894	-19.795	-66.37
Cash From Operating Activities	-65.066	-49.777	-33.864	-16.289	-53.667
Cash From Operating Activities	2.723	1.995	1.298	0.64	2.167
Non-Cash Items	5.706	3.55	2.716	1.545	11.173
Cash Interest Paid	2.71	1.803	0.845	0	0
Changes in Working Capital	4.03	2.569	1.016	1.321	-0.637
Cash From Investing Activities	-2.952	-2.532	-1.64	-1.334	-5.366
Capital Expenditures	-2.714	-2.619	-1.64	-1.334	-3.986
Cash From Financing Activities	34.056	34.055	33.255	30.221	70.847
Financing Cash Flow Items	-2.773	-2.773	-2.761	-2.683	-1.381
Issuance (Retirement) of Stock, Net	6.829	6.828	6.016	2.904	72.228
Net Change in Cash	-33.962	-18.254	-2.249	12.598	11.814
Other Investing Cash Flow Items, Total	-0.238	0.087	0		-1.38
Issuance (Retirement) of Debt, Net	30	30	30	30	0

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Mustang Bio, Inc. Company profile

About Mustang Bio Inc

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Its pipeline is focused on three core areas: gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies and CAR T therapies for solid tumors. Its products include MB-107 and MB-207 is Ex vivo Lentiviral Therapy for X-linked Severe Combined Immunodeficiency (XSCID). XSCID is a rare genetic immune system condition also known as bubble boy disease. Its MB-102 is a CD123 CAR T cell Program for blastic plasmacytoid dendritic cell neoplasm (BPDCN), acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

Financial summary

BRIEF: For the nine months ended 30 September 2021, Mustang Bio Inc revenues was not reported. Net loss increased 18% to $46.3M. Higher net loss reflects Research and development - Balan increase of 35% to $33.4M (expense), General and administrative - Balancin increase of 28% to $7.5M (expense), Stock-based Compensation in R&D increase of 41% to $1.6M (expense).

Industry:

Bio Therapeutic Drugs

377 Plantation Street
01605

Income Statement

Annual
Quarterly

News

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

12:39, 30 November 2023

Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

EZ PI expected to drop further but speed of decline

08:16, 29 November 2023

A weaker Dollar drives gold higher

Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

13:49, 28 November 2023

Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

13:20, 28 November 2023

RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

13:04, 28 November 2023